LY 3185643
Alternative Names: LY3185643Latest Information Update: 28 Dec 2019
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypoglycaemia
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Hypoglycaemia(In volunteers) in Singapore (SC, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Hypoglycaemia(In volunteers) in United Kingdom (SC, Injection)
- 01 Mar 2017 Eli Lilly completes a phase I pharmacokinetics/pharmacodynamics trial in Healthy volunteers in Singapore (NCT02951780)